Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria.

ABSTRACT:

Background

Lenvatinib is one of the first-line treatments for unresectable hepatocellular carcinoma (HCC). However, data are lacking on lenvatinib in the postoperative setting.

Methods

This retrospective analysis enrolled 242 patients with HCC who underwent liver transplantation (LTx). Eligible patients were divided into 2 groups according to their use of adjuvant lenvatinib following LTx (lenvatinib, n=42; control, n=200). The primary outcome measures were overall survival (OS), time to recurrence (TTR), and safety. Kaplan-Meier analysis was applied to calculate the OS, while a competing risk model was used to estimate the cumulative incidence of recurrence.

Results

The lenvatinib group showed more advanced tumors and a higher proportion of HCC beyond the Milan crite

SUBMITTER: Guo DZ 

PROVIDER: S-EPMC9652551 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature